Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 9/2012

01-09-2012 | Original paper

An exploratory analysis of common genetic variants in the vitamin D pathway including genome-wide associated variants in relation to glioma risk and outcome

Authors: Gabriella M. Anic, Reid C. Thompson, L. Burton Nabors, Jeffrey J. Olson, James E. Browning, Melissa H. Madden, F. Reed Murtagh, Peter A. Forsyth, Kathleen M. Egan

Published in: Cancer Causes & Control | Issue 9/2012

Login to get access

Abstract

Purpose

Experimental and epidemiological evidence shows a beneficial role of vitamin D in cancer. In vitro evidence is consistent with a similar protective function in glioma; however, no study has yet examined the potential role of vitamin D in glioma.

Methods

We evaluated the association between common genetic variants in the vitamin D pathway and glioma risk and patient outcome in 622 newly diagnosed glioma cases and 628 healthy controls enrolled in a clinic-based case–control study. Subjects were genotyped for 7 candidate and tagging single nucleotide polymorphisms in the vitamin D receptor and 8 additional variants in NADSYN1, GC, CYP24A1, CYP2R1, and C10ORF88 linked in genome-wide association studies to serum concentrations of vitamin D. Unconditional logistic regression was used to estimate age- and gender-adjusted odds ratios and 95 % confidence intervals for glioma risk according to vitamin D genotypes. Proportional hazards regression was used to estimate hazard ratios for glioma-related death among 320 patients diagnosed with high-grade tumors. P values were uncorrected for multiple comparisons.

Results

Risk of astrocytic tumors was associated with variant alleles in rs3829251 (NADSYN1), rs10741657 (CYP2R1), rs2228570 (Fok1, VDR), and rs731236 (Taq1, VDR). No risk associations were found among oligodendroglial tumors. Survival associations were observed according to variant status for rs1544410 (Bsm1, VDR) and rs6013897 (CYP24A1).

Conclusion

This exploratory analysis provides limited evidence of a role for genetic variation in vitamin D pathway genes with glioma risk and survival.
Literature
1.
Hansen CM, Binderup L, Hamberg KJ, Carlberg C (2001) Vitamin D and cancer: effects of 1,25(OH)2D3 and its analogs on growth control and tumorigenesis. Front Biosci 6:D820–D848PubMedCrossRef
2.
Garland CF, Gorham ED, Mohr SB et al (2007) Vitamin D and prevention of breast cancer: pooled analysis. J Steroid Biochem Mol Biol 103:708–711PubMedCrossRef
3.
Touvier M, Chan DS, Lau R et al (2011) Meta-analyses of vitamin d intake, 25-hydroxyvitamin d status, vitamin d receptor polymorphisms, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 20:1003–1016PubMedCrossRef
4.
Freedman DM, Looker AC, Chang SC, Graubard BI (2007) Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst 99:1594–1602PubMedCrossRef
5.
Giovannucci E, Vitamin D (2009) and cancer incidence in the Harvard cohorts. Ann Epidemiol 19:84–88PubMedCrossRef
6.
Helzlsouer KJ (2010) Overview of the cohort consortium Vitamin D pooling project of rarer cancers. Am J Epidemiol 172:4–9PubMedCrossRef
7.
Giovannucci E, Liu Y, Rimm EB et al (2006) Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 98:451–459PubMedCrossRef
8.
Mohr SB, Gorham ED, Garland CF, Grant WB, Garland FC (2010) Low ultraviolet B and increased risk of brain cancer: an ecological study of 175 countries. Neuroepidemiology 35:281–290PubMedCrossRef
9.
Elias J, Marian B, Edling C et al (2003) Induction of apoptosis by vitamin D metabolites and analogs in a glioma cell line. Recent Results Cancer Res 164:319–332PubMed
10.
Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ (2005) Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat 29:21–30PubMedCrossRef
11.
Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP (2004) Genetics and biology of vitamin D receptor polymorphisms. Gene 338:143–156PubMedCrossRef
12.
Fang Y, van Meurs JB, d’Alesio A et al (2005) Promoter and 3′-untranslated-region haplotypes in the vitamin d receptor gene predispose to osteoporotic fracture: the Rotterdam study. Am J Hum Genet 77:807–823PubMedCrossRef
13.
Wang TJ, Zhang F, Richards JB et al (2010) Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 376:180–188PubMedCrossRef
14.
Ahn J, Yu K, Stolzenberg-Solomon R et al (2010) Genome-wide association study of circulating Vitamin D levels. Hum Mol Genet 19:2739–2745PubMedCrossRef
15.
Egan KM, Thompson RC, Nabors LB, et al. (2011) Cancer susceptibility variants and the risk of adult glioma in a US case-control study. J Neurooncol
16.
Permuth-Wey J, Thompson RC, Burton Nabors L et al (2011) A functional polymorphism in the pre-miR-146a gene is associated with risk and prognosis in adult glioma. J Neurooncol 105:639–646PubMedCrossRef
17.
Shete S, Hosking FJ, Robertson LB et al (2009) Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet 41:899–904PubMedCrossRef
18.
Wrensch M, Jenkins RB, Chang JS et al (2009) Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet 41:905–908PubMedCrossRef
19.
Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061–1068CrossRef
20.
Whitfield GK, Remus LS, Jurutka PW et al (2001) Functionally relevant polymorphisms in the human nuclear Vitamin D receptor gene. Mol Cell Endocrinol 177:145–159PubMedCrossRef
21.
Denzer N, Vogt T, Reichrath J (2011) Vitamin D receptor (VDR) polymorphisms and skin cancer: a systematic review. Dermatoendocrinol 3:205–210PubMed
22.
Kostner K, Denzer N, Muller CS, Klein R, Tilgen W, Reichrath J (2009) The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res 29:3511–3536PubMed
23.
McCullough ML, Bostick RM, Mayo TL (2009) Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer. Annu Rev Nutr 29:111–132PubMedCrossRef
24.
McKay JD, McCullough ML, Ziegler RG et al (2009) Vitamin D receptor polymorphisms and breast cancer risk: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev 18:297–305PubMedCrossRef
25.
Davies JR, Chang YM, Snowden H et al (2011) The determinants of serum vitamin D levels in participants in a melanoma case-control study living in a temperate climate. Cancer Causes Control 22:1471–1482PubMedCrossRef
26.
Simon KC, Munger KL, Kraft P, Hunter DJ, De Jager PL, Ascherio A (2011) Genetic predictors of 25-hydroxyvitamin D levels and risk of multiple sclerosis. J Neurol 258:1676–1682PubMedCrossRef
27.
Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109PubMedCrossRef
Metadata
Title
An exploratory analysis of common genetic variants in the vitamin D pathway including genome-wide associated variants in relation to glioma risk and outcome
Authors
Gabriella M. Anic
Reid C. Thompson
L. Burton Nabors
Jeffrey J. Olson
James E. Browning
Melissa H. Madden
F. Reed Murtagh
Peter A. Forsyth
Kathleen M. Egan
Publication date
01-09-2012
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 9/2012
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-012-0018-7

Other articles of this Issue 9/2012

Cancer Causes & Control 9/2012 Go to the issue

Original paper

Prospective study of cytomegalovirus serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial

Original paper

DNA methyltransferase 3b (DNMT3b), tumor tissue DNA methylation, Gleason score, and prostate cancer mortality: investigating causal relationships

Brief report

Validation of AJCC TNM staging for breast tumors diagnosed before 2004 in cancer registries

Original paper

Effects of phenotypes in heterocyclic aromatic amine (HCA) metabolism–related genes on the association of HCA intake with the risk of colorectal adenomas

Original paper

Brain tumors in children and adolescents and exposure to animals and farm life: a multicenter case–control study (CEFALO)

Original paper

Influence of individual and social contextual factors on changes in leisure-time physical activity in working-class populations: results of the Healthy Directions–Small Businesses Study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits